Anteris Technologies Global Corp. Grants Contingent Equity Awards to Executives

What Happened
Anteris Technologies Global Corp. announced on Sept. 17, 2026 (filing) that on Sept. 12, 2026 the board approved contingent grants of stock options and performance-based restricted stock units (PSUs) for executives, with a grant date of Sept. 13, 2026. The grants include options for CEO Wayne Paterson (1,200,000 options) and CFO David St Denis (414,000 options), PSUs of 800,000 for Paterson and 485,000 for St Denis, and an options award for Matthew McDonnell (target value $500,000). All grants are subject to the company’s Equity Incentive Plan, clawback/forfeiture terms, and are contingent on stockholder approval.

Key Details

• Options: Paterson 1,200,000 and St Denis 414,000; grant date 9/13/2026; expiration 9/13/2036; exercise price = fair market value on grant date. Total named options = 1,614,000.
• PSUs: Paterson 800,000 and St Denis 485,000 (total 1,285,000); five-year performance period; vesting tied to VWAP hurdles: 30% at $21.50, +30% at $41.00, +40% at $61.50 (60-trading-day VWAP tests). Dividend equivalents credited as additional PSUs where applicable.
• Vesting & terminations: Standard continuous-employment vesting (options generally vest over 3–4 years depending on grant). Death or permanent disability generally causes full vesting; other termination rules vary by grant (e.g., Paterson pro-rata vesting on termination without cause or for good reason; St Denis forfeits unvested on most terminations).
• Change in control: If awards are not continued by the surviving entity they generally vest in full; if continued but holder is terminated without cause or for good reason within 24 months after the change in control, awards generally vest in full.

Why It Matters
These grants increase potential future dilution (options and PSUs totaling millions of shares if fully vested and paid) and tie a material portion of executive compensation to stock-price performance and continued service. Because the awards are contingent on shareholder approval, they are not yet effective. Investors should note the multi-year performance hurdles and the change-in-control and termination provisions, which affect when and whether these awards would convert into shares or cash.